BTIG has appointed Yun Zhong PhD as a publishing analyst in the firm’s Healthcare Equity Research team.
Zhong’s research coverage will focus on the biotechnology subsector, where he will specialise in gene therapy, genetic medicine, targeted therapy, rare disease and haematology. In his new role, he joins the firm as a Director within the Research and Strategy division, where he will report to Ryan Serwin, CFA, Director of Research, at BTIG.
“We are very pleased to welcome Yun to the BTIG Biotechnology Equity Research team,” says Serwin. “Biotechnology continues to be one of the most active subsectors for clients of our healthcare practice. We believe that Yun’s decade of experience covering biotechnology companies makes him exceedingly qualified to help clients evaluate their investment opportunities in the space.”
Prior to BTIG, hong was a Biotech Equity Research Analyst at Berenberg Capital Markets. Previously, he was Director within Biotech Equity Research at Janney Montgomery Scott. Earlier in his career, Zhong was a Vice President within Biotech Equity Research at SunTrust Robinson Humphrey, and a Biotech Equity Research Associate at Cowen. He earned a PhD in molecular biology and neuroscience from Rockefeller University, as well as an MS and BS in biophysical engineering from Osaka University.
Zhong joins BTIG’s established team of publishing Biotechnology Analysts including Bert Hazlett, Thomas Shrader, PhD, CFA, Justin Zelin and Julian Harrison. Biotechnology continues to be a core area of growth for the firm which increasingly offers differentiated and actionable expertise for institutional and corporate clients.
BTIG Research and Strategy provides comprehensive reports, industry observations and other insights for clients. The team’s sector focus includes consumer, energy and infrastructure, financials, healthcare, real estate, as well as technology, media and telecommunications.
